Background: The aim of this study was to analyze the association between radiation therapy (RT) for rectal cancer and the development of second tumors.
Introduction
The prognosis of rectal cancer has improved substantially over the last decades [1] . This has mainly been the result of advances in imaging techniques, pre-operative (chemo)radiation therapy (CRT) and total mesorectal excision (TME) surgery [2] . Radiation therapy (RT) is often part of the treatment regimen for rectal cancer patients. In intermediate risk tumors, short-course RT (5 Â 5 Gy) followed by immediate surgery, is used in patients to reduce the chances of a local recurrence [3] [4] [5] . In the case of locally advanced rectal cancer (LARC), long-course CRT is given followed by surgery after several weeks, during which the tumor typically shows downsizing and downstaging [6] [7] [8] [9] [10] . However, RT has also been associated with adverse effects which may manifest during RT (acute toxicity) or after an interval of months or years (late toxicity) [2, 11] .
One form of late toxicity is the supposed increased risk of second tumors in the irradiated field [12] . Second tumors are commonly seen in all survivors of cancer [13] , and it is conceived that the development of second tumors is the result of a combination of etiological factors. Not only do genetic susceptibility, lifestyle, and environmental factors contribute to this development, but also the treatment of the primary cancer may increase the risk of developing a second tumor [12, 14] . The literature is inconsistent regarding the role of pelvic RT in the development of second tumors. Some studies have reported an increased risk of second tumors after RT while others found no increased risk [12, [14] [15] [16] [17] . Comparison of the outcomes in the literature is challenging due to the different statistical methods that have been used. In addition, the sample size of most studies is small and large patient numbers with a considerable follow-up are needed in order to draw firm conclusions.
The present study aimed to compare the incidence of second tumors between patients who did, or did not, receive RT for primary rectal cancer in a nationwide setting including >29 000 patients. In addition, the incidence of second tumors in the cohort was compared with the incidence of sporadic tumors in the general population.
Methods
In the Netherlands, all newly diagnosed tumors, except for basal carcinomas of the skin, are registered in the nationwide population-based Netherlands Cancer Registry (NCR). Data regarding diagnosis and treatment are collected from patient files by trained registrars. The International Classification of Diseases for Oncology (ICD-O) is used for coding topography and morphology. Cancers are staged according to the TNM classification.
Data of all surgically treated rectal cancer patients in the Netherlands who were diagnosed between 1989 and 2007 were retrieved from the NCR. Patients were only included in case of rectal cancer as first malignancy. Patients who had clinical or pathological evidence of metastatic disease at the time of the primary cancer were excluded (n ¼ 3077). Patients with a follow-up of zero days were excluded as well (n ¼25). Follow-up on all other patients was complete up to 31st December 2014 by linkage to the nationwide municipal population registries network and thus patients had a minimum of 7 years follow-up, unless died earlier.
Tumors that developed within the irradiation volume, subsequently referred to as pelvic tumors, were analyzed separately. These included tumors of the urinary bladder, urethra, uterus, ovary, vagina, prostate, anus, rectum, recto sigmoid, pelvic bones, and pelvic lymphomas. Small bowel and colon cancers were not included in the pelvic tumor selection.
Statistical analysis
To estimate the cumulative incidence of developing a second cancer, Fine and Grays competing risk model was used with death as a competing event [18] . The statistical difference between the cumulative incidence of second cancers between patients who were or were not treated with RT for their primary rectal cancer was estimated.
Standardized Incidence Ratios (SIR) were calculated for comparison with the incidence of primary tumors in the general population. SIR were defined as the ratio of observed second cancers to expected cases in the Dutch general population and were stratified by age, gender, and calendar time. The background incidence of cancers was derived from data provided by the NCR. The absolute excess risk (AER) per 10 000 personyears was calculated as the number of observed cases (e.g. second primary cancers) minus the expected cases divided by person-years of follow-up.
Multivariable analysis was conducted by Cox proportional hazard regression and variables were selected by significant outcomes (P < 0.1) in univariable analysis and clinical relevance. Statistical significance was defined as P < 0.050. IBM SPSS statistics (version 20.0) was used for analyses concerning characteristics and survival. Competing risk analyses were conducted using Stata (version 13.1) and SIR were calculated in SAS (software 9.2).
Results
The cohort consisted of 29 027 rectal cancer patients, of which 15 467 patients were treated with RT. Patient demographics are depicted in Table 1 . Median follow-up was 8.1 years (range 0-27) in the RT group and 7.1 years (range 0-27) in the non-irradiated group (NRT; P < 0.001). The SIR for any second cancer was 1.16 (CI 1.12-1.19), resulting in 27.7 excess cases per 10 000 patients per year in patients treated for rectal cancer compared with the general population. This did not differ between patients who did or did not receive RT. All SIR and AER values are depicted in supplementary Table S1 , available at Annals of Oncology online.
A total of 4398 patients were diagnosed at least once with a second primary cancer: 2204 (14.2%) patients in the RT-group and 2194 (16.2%) patients in NRT-group (supplementary Figure S1 , available at Annals of Oncology online; P < 0.001). The median interval between diagnosis of the primary and second tumor was 5 years in both the RT-group and the NRT-group. The most common cancers were respiratory (n ¼ 712), skin (n ¼ 636), prostate (n ¼ 560), colon (n ¼ 458), and breast cancer (n ¼ 414; Table 2 and supplementary Figure S2 , available at Annals of Oncology online). Crude incidence risks of second tumors after 5, 10, 15, 20, and 25 years of follow-up were 7.1%, 11.4%, 13.4%, 14.1%, and 14.2% in the RT-group and 7.9%, 11.9%, 14.5%, 15.6%, and 16.2% in the NRT-group respectively (P < 0.001; Figure 1 ). The incidence of second tumors differentiated for age and RT is depicted in supplementary Table S2 , available at Annals of Oncology online.
Cumulative incidence risks
RT reduced the cumulative incidence of second pelvic tumors compared with patients who did not receive RT (subhazard ratio [SHR] 0.77, 95% CI 0.68-0.88; Figure 2A ). This was confirmed in a multivariable analysis (P ¼ 0.04), corrected for age, gender, year of incidence of rectal cancer, histology, differentiation, pathological tumor and nodal stage, post-operative chemotherapy, and vital status (HR 0.86, 95% CI 0.74-0.99; supplementary Table S3 , available at Annals of Oncology online). The median interval between diagnosis of the primary rectal cancer and a second pelvic cancer was 6 years (range 0-25) in the RT-group and 5 years in the NRT-group (range 0-23). There was no difference in the incidence of second tumors outside the pelvis between patients who did or did not receive RT (SHR 0.98, 95% CI 0.92-1.05).
Organ specific analyses showed that second prostate tumors were less common in the RT group compared with the NRT group (SHR 0.54, 95% CI 0.46-0.64; Figure 2B ). This was confirmed in a multivariable analysis in men corrected for age, year of incidence of rectal cancer, pathological tumor and nodal stage, post-operative chemotherapy, and vital status (HR 0.57, 95% CI 0.46-0.69; supplementary Table S4 , available at Annals of Oncology online). RT also reduced the risk for a second tumor in the rectum and recto sigmoid compared with patients who did not receive RT (SHR 0.53, 95% CI 0.33-0.85; Figure 2C ). However, this was not significant in a multivariable analysis (HR 0.63, 95% CI 0.36-1.09; supplementary Table S4 , available at Annals of Oncology online). Gynecological tumors occurred more often in the RT group compared with the NRT group (SHR 1.49, 95% CI 1.11-2.00; Figure 2D ), which was confirmed during multivariable analysis in females (HR 1.54, 95% CI 1.09-2.17; supplementary Table S4 , available at Annals of Oncology online). The median interval between diagnosis of the primary rectal cancer and a second gynecological tumor was 8 years (range 0-25) in the RT-group and 6 years (range 0-20) in the NRT-group. Analysis of urological, anus, and hematological malignancies did not show any significant differences in incidence between the RT-and NRT-group. Censoring all second tumors that occurred in the first two years after diagnosis of the primary rectal cancer did not affect the differences between the two treatment groups (results not shown).
Gender specific analyses showed that RT reduced the risk of a second pelvic tumor in men (SHR 0.63, 95% CI 0.55-0.73). However, when prostate cancer was left out of the cumulative incidence risk analysis, there was no longer a significant relationship between the occurrence of second pelvic tumors and previous RT. In females, the overall risk of a second pelvic cancer was not related to previous administration of RT (SHR 1.19, 95% CI 0.93-1.52).
Discussion
The risk of developing a second pelvic tumor has traditionally been conceived one of the disadvantages of RT in the treatment of rectal cancer patients. Data from this large population-based study on rectal cancer patients demonstrate that overall there is no increase in second tumors following RT. There even seems to be a protective effect of RT, which was found pre-dominantly for prostate cancer. Gynecological tumors however, occurred more often after RT. Patients with previous rectal cancer had a marginally increased risk of a second tumor compared with the general population, which was irrespective of RT.
Few studies have shown an increase of second tumors following RT. A Swedish study by Birgisson et al. [12] (n ¼ 1599) suggested that RT for rectal cancer increases the probability of developing a second tumor for organs within or adjacent to the irradiation field. This assumption was later supported by a study using data from the SEER cancer registry (n ¼ 3713), which showed a small increase of second solid cancers in patients treated with RT [14] . However, a larger (n ¼ 21 000) and more recent study from the SEER cancer registry reported no significant difference in the incidence of second tumors between the irradiated and the non-irradiated cohort after multivariable analysis [16] . Furthermore, a pooled analysis (n ¼ 1413) by Wiltink et al. [15] also concluded that previous RT for rectal cancer did not result in a higher probability for a second tumor. These last two studies are in accordance with the findings from the current study, which is the largest study in the literature. Outcomes extracted from the key literature on this topic and the present study results are summarized in supplementary Table S5 , available at Annals of Oncology online.
In men, a protective effect of RT was found on the development of second tumors. In females, however, the results did neither show a beneficial effect, nor a detrimental effect of RT on the overall risk of developing a second tumor. The difference between genders can be explained by the protective effect that was found on the development of prostate tumors, which has also been described in studies using data of the SEER cancer registry [16, 19] . The protective effect on the development of prostate cancer is probably due to 'incidental' radiation of the prostate when treating the rectum, which could prevent or delay the development of prostate cancer. A potential similar effect has been reported in which patients who were irradiated for prostate cancer had a similarly decreased risk for a subsequent rectal cancer [21] . It has also been suggested that hormonal changes due to scattered radiation to the testes during RT of the rectum may decrease the likelihood of developing prostate cancer [20] . However, the testes are not located in the irradiation volume and scattered radiation dosages delivered to the testes are low (1-2 Gy) [20] . The cumulative incidence of second gynecological tumors was higher in females who received RT for the primary cancer. The increase in second gynecological tumors did not result in an overall increased risk for second tumors in female patients who received RT in comparison with patients who did not receive RT. An increased risk for tumors of the uterine corpus and cervix after RT was also reported by Kendal et al. [21] with a hazard ratio of 2.5 (95% CI 1.6-4.0). The authors did not perform competing risk analysis, which makes the results more difficult to interpret. Other studies did not show an increased risk of gynecological tumors [12, 15] .
Data on timing of RT was unavailable in the majority of patients and the effect of pre-operative versus post-operative RT could therefore not be studied. Also, before the turn of the century, both pre-operative RT and post-operative RT were administered on a regular basis. After 2000, there was a shift towards pre-operative RT becoming the preferential treatment while post-operative RT was almost completely abandoned [22] . A study using data from the SEER cancer registry has reported a higher incidence of second tumors after pre-operative RT for rectal cancer compared with patients who were treated post-operatively [17] . However, a weakness in studies comparing the long-term effects after either preversus post-operative RT is a difference in compliance between these two treatment regimens. A prospective study form Sauer et al. [23] showed that only 54% of post-operatively treated patients received the full dose of RT versus 92% of patients who received pre-operative treatment (P < 0.001).
Distinguishing a new primary cancer in the rectum or rectosigmoid from a local recurrence can be challenging. The NCR does not register data on recurrences and follows strict guidelines to discriminate new primary tumors from recurrences. Nevertheless, it is not inconceivable that some tumors have erroneously been regarded as a primary tumor instead of a recurrence. However, the number of second rectum and rectosigmoid tumors in the cohort is low (n ¼ 75), and misjudgment is likely to have affected both groups equally.
Our findings showed that patients with previous rectal cancer had a marginally increased risk of developing a second tumor compared with the general Dutch population. This is in accordance with findings from previous studies [15, 24, 25] and supports the hypothesis that the development of second tumors is probably the result of a combination of factors, including lifestyle, environment, and genetic susceptibility. Factors contributing to the development of the primary cancer probably also play a role in the development of a second cancer.
The strength of the present study is the populationbased analysis of a large number of rectal cancer patients (n ¼ 29 024). All patients had at least 7 years follow-up or deceased earlier, because follow-up was retrieved in 2014 for patients treated between 1989 and 2007. The longest follow-up was 27 years, with over 10 years of follow-up in >10 000 patients. To the best of our knowledge, this is the largest cohort that has been studied on the incidence of second cancers following RT for rectal cancer. A median follow-up of 7.7 years might seem short in this perspective, but is in line with the median survival of rectal cancer patients [26] . Furthermore, there was no trend towards a higher incidence of second tumors at the end of follow-up (Figure 1) . The results, however, must be interpreted with caution due to the retrospective nature of the study. The study spans over a period of time in which knowledge and attitude toward RT, staging techniques, and pathology reporting have changed significantly [22, 26, 27] . This may have introduced a potential bias, but should have affected both groups equally. Unfortunately, data on RT dosages and fractionation were not available and could therefore not be studied. Furthermore, the NRT-group might have been randomly enriched with elderly patients or patients with more co morbidities and as such a possible higher risk on developing second tumors. Yet, during multivariable analysis, there was no overall higher risk on developing second tumors outside of the pelvis for non-irradiated patients.
Conclusion
In the current population-based study, patients who were diagnosed with non-metastatic rectal cancer and underwent surgery had a marginally increased risk for the development of a second tumor compared with the general population. RT seemed to have a protective effect on the development of second pelvic tumors other than gynecological tumors. These findings are highly important and can contribute to improved patient counseling. Future studies will need to be undertaken to show whether these findings can be extrapolated to other malignancies.
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